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Diabetic nephropathy is the leading 
cause of end-stage renal disease in 
industrialized countries. It is believed 
that the pathophysiological origin of 
diabetic nephropathy lies in a combi-
nation of hemodynamic and metabolic 
abnormalities that primarily aﬀect the 
glomerulus.1 A widely accepted model 
assumes a primary injury to the podo-
cyte, which constitutes the main cause 
of proteinuria and initiates dysregula-
tion of the mesangial compartment, 
resulting in glomerulosclerosis.2 Several 
molecules are thought to participate in 
the progression of glomerular injury. 
One of the most prominent examples is 
transforming growth factor-β (TGFβ), 
which is overexpressed in diabetic 
glomeruli and is known to propagate 
the deposition of extracellular matrix 
proteins and to inhibit the expression 
of matrix metalloproteinases involved 
in their degradation. On the basis of 
evidence from studies in the develop-
ing embryo and in various disease mod-
els, many of the eﬀects of TGFβ seem 
to be mediated by an activation of the 
expression of connective tissue growth 
factor (CTGF), a member of the fam-
ily of CCN proteins (named after their 
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Marked upregulation of the secreted extracellular matrix-associated 
protein connective tissue growth factor (CTGF) in the glomerulus 
coincides with the onset of diabetic nephropathy. Recent studies, 
including the one by Yokoi et al., shed light on the role of CTGF in 
glomerular injury.
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founding members Cyr61, CTGF, and 
Nov). Where examined, CCN proteins 
are multifunctional modular proteins 
that act as extracellular matrix-asso-
ciated molecules. They regulate such 
diverse cellular processes as adhesion, 
migration, mitogenesis, diﬀerentiation, 
and survival.
CTGF was ﬁrst identiﬁed as a poten-
tial player in the molecular network of 
the diabetic glomerulus, when it was 
shown by subtractive hybridization 
that its expression was upregulated in 
mesangial cells exposed to high glu-
cose.3 Furthermore, CTGF expression 
was upregulated in podocytes and 
mesangial cells in several animal mod-
els of diabetic nephropathy as well as 
in early and late diabetic nephropathy 
in humans.1 Additional evidence for 
an involvement of CTGF in glomeru-
lar pathology was derived from a large 
body of in vitro experiments on cultured 
mesangial cells, which upregulate CTGF 
expression in response to high glucose 
concentrations and respond to CTGF 
by an increased production of extracel-
lular matrix proteins and an induction 
of cytoskeletal rearrangements.1,4 Little 
was known about whether or not these 
ﬁndings are relevant in the in vivo situ-
ation, before a recent study5 provided 
evidence that a knock-down of CTGF 
expression in vivo using antisense oli-
gonucleotides ameliorated diabetic 
nephropathy in mouse models of type 
1 and type 2 diabetes mellitus. This was 
associated with decreases in serum crea-
tinine and proteinuria as well as with 
a reduced mesangial matrix expansion 
and reduced expression of extracel-
lular matrix components known to be 
involved in glomerulosclerosis and tubu-
lointerstitial ﬁbrosis. Taken together, 
these observations are suggestive of a 
model in which most if not all of the 
eﬀects of increased TGFβ signaling in 
the diabetic glomerulus are mediated 
by CTGF.
A new study by Yokoi et al.6 (this 
issue) adds some exciting twists to this 
story. The authors generated transgenic 
mice that overexpress CTGF under the 
control of the 1.5 kb nephrin promoter, 
which conﬁnes expression exclusively 
to podocytes. This model would make 
it possible to test whether an upregu-
lation of CTGF in the glomerulus by 
itself is suﬃcient to mediate glomerular 
pathology in vivo. Somewhat surpris-
ingly, the mice were normal at base-
line and revealed neither glomerular 
abnormalities nor signiﬁcant proteinu-
ria. However, when challenged in the 
setting of a streptozotocin-induced 
model of type 1 diabetes, these mice 
performed signiﬁcantly worse than their 
wild-type littermates. This was evident 
by an increased albuminuria, enhanced 
expansion of glomerular mesangial area, 
electron microscopic evidence of podo-
cyte vacuolation, and reduced numbers 
of podocytes in transgenic glomeruli. 
Although the expression of extracel-
lular matrix components in glomeruli 
was unchanged, the activity of the 
matrix-degrading enzyme matrix metal-
loproteinase-2 was reduced in trans-
genic diabetic animals compared with 
non-transgenic diabetics, providing a 
potential explanation for the observed 
matrix expansion.
The most remarkable conclusion from 
this study is that CTGF itself is not suf-
ﬁcient to induce glomerular pathology. 
Instead it seems to require the presence 
of additional changes in the glomerular 
microenvironment that are provided 
in the setting of diabetic nephropathy. 
What are these costimulatory signals? 
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An obvious candidate is the onset of 
TGFβ signaling in diabetic nephropathy 
(Figure 1). CTGF is known to depend 
on the presence of TGFβ to exert its 
biological activity in multiple instances. 
In fact, an elegant study showed that 
CTGF directly interacts with TGFβ1 and 
potentiates its binding to the TGFβ type 
II receptor.7 At the same time, CTGF 
interacts with other signaling pathways. 
CTGF was shown to physically inter-
act with bone morphogenetic proteins 
(BMPs), resulting in an inhibition of 
BMP binding to the BMP Ia receptor and 
impaired downstream signaling.7 Inter-
estingly, in the kidney, BMP signaling 
appears to potently antagonize TGFβ-
mediated matrix expansion, which has 
been extensively studied in animal mod-
els of renal ﬁbrosis.8 In addition, a recent 
study indicated that BMP signaling may 
be protective in the setting of diabetic 
nephropathy.9 Therefore, CTGF may 
simultaneously aﬀect TGFβ and BMP 
signaling in the diabetic glomerulus, 
thereby tipping the balance toward the 
detrimental actions of TGFβ.
Clearly, this idea requires further 
studies, as other changes in the diabetic 
glomerulus may explain the increased 
responsiveness to CTGF. For instance, 
CTGF potentially elicits direct and rapid 
eﬀects in its target cells, which are inde-
pendent of TGFβ signaling (Figure 1). 
This is thought to be mediated by cell 
membrane-associated receptors from 
diverse protein families, including 
integrins and neurotrophin recep-
tors.10,11 Therefore, increased expression 
or responsiveness of these receptors in 
the setting of diabetic nephropathy may 
contribute to CTGF eﬀects. On the other 
hand, CTGF has been shown to aﬀect 
yet another pathway, WNT signaling, by 
interacting with the WNT co-receptor 
LRP6 and inhibiting WNT-dependent 
signal transduction.12 WNT signal-
ing is crucially important during renal 
development but may be reactivated 
in the setting of renal disease. Interest-
ingly, it was recently reported that WNT 
signaling via its intracellular signaling 
mediator β-catenin inhibits apoptosis 
of cultured mesangial cells in response 
to high glucose concentrations.13 In the 
same study, activation of β-catenin sign-
aling by a pharmacological agent in mice 
reduced proteinuria in the setting of 
streptozotocin-induced diabetes. Con-
sequently, one may envision that CTGF 
dampens protective WNT signals in the 
setting of diabetic nephropathy, thereby 
expanding its detrimental repertoire.
Although still at the early specula-
tive stages, a model can be proposed 
where CTGF represents an extracellular 
matrix-associated integrative hub in the 
center of multiple signaling pathways in 
the diseased diabetic glomerulus (Figure 
1). This mode of CTGF action may help 
in locally enhancing TGFβ signaling 
and/or attenuating the BMP and WNT 
pathways to ﬁne-tune matrix turnover 
and cellular survival. Therefore, CTGF 
antagonism as a potential therapeutic 
intervention may turn out to act at the 
center of multiple pathways that modify 
the disease process. The elucidation of 
individual contributions of the various 
potential molecular targets of CTGF in 
diabetic nephropathy will be an exciting 
challenge for the future.
REFERENCES
1. Forbes JM, Fukami K, Cooper ME. Diabetic 
nephropathy: where hemodynamics meets 
metabolism. Exp Clin Endocrinol Diabetes 2007; 
115: 69–84.
2. Wolf G, Chen S, Ziyadeh FN. From the periphery 
of the glomerular capillary wall toward the 
center of disease: podocyte injury comes of 
age in diabetic nephropathy. Diabetes 2005; 54: 
1626–1634.
3. Murphy M, Godson C, Cannon S et al. 
Suppression subtractive hybridization identifies 
high glucose levels as a stimulus for expression 
of connective tissue growth factor and other 
genes in human mesangial cells. J Biol Chem 
1999; 274: 5830–5834.
4. Furlong F, Crean J, Thornton L et al. Dysregulated 
intracellular signaling impairs CTGF-stimulated 
responses in human mesangial cells exposed 
to high extracellular glucose. Am J Physiol Renal 
Physiol 2007; 292: F1691–F1700.
5. Guha M, Xu ZG, Tung D et al. Specific down-
regulation of connective tissue growth factor 
attenuates progression of nephropathy in 
mouse models of type 1 and type 2 diabetes. 
FASEB J 2007; 21: 3355–3368.
6. Yokoi H, Mukoyama M, Mori K et al. Overexpression 
of connective tissue growth factor in podocytes 
deteriorates diabetic nephropathy in mice. Kidney 
Int 2008; 73: 446–455.
7. Abreu JG, Ketpura NI, Reversade B et al. 
Connective-tissue growth factor (CTGF) 
modulates cell signalling by BMP and TGF-beta. 
Nat Cell Biol 2002; 4: 599–604.
8. Patel SR, Dressler GR. BMP7 signaling in renal 
development and disease. Trends Mol Med 2005; 
11: 512–518.
9. Wang S, de Caestecker M, Kopp J et al. Renal 
bone morphogenetic protein-7 protects against 
diabetic nephropathy. J Am Soc Nephrol 2006; 17: 
2504–2512.
10. Wahab NA, Weston BS, Mason RM. Connective 
tissue growth factor CCN2 interacts with and 
activates the tyrosine kinase receptor TrkA. J Am 
Soc Nephrol 2005; 16: 340–351.
11. Lau LF, Lam SC. The CCN family of angiogenic 
regulators: the integrin connection. Exp Cell Res 
1999; 248: 44–57.
12. Mercurio S, Latinkic B, Itasaki N et al. Connective-
tissue growth factor modulates WNT signalling 
and interacts with the WNT receptor complex. 
Development 2004; 131: 2137–2147.
13. Lin CL, Wang JY, Huang YT et al. Wnt/beta-
catenin signaling modulates survival of high 
glucose-stressed mesangial cells. J Am Soc 
Nephrol 2006; 17: 2812–2820.
Figure 1 | Local modulation of signaling activity by CTGF. CTGF modulates the WNT, bone 
morphogenetic protein (BMP), and transforming growth factor-β (TGFβ) pathways but also signals 
directly via known and putative receptors, thereby potentiating harmful and inhibiting protective 
signals. Although the indicated interactions have been demonstrated in various biological systems, 
their individual roles in diabetic nephropathy remain to be determined. FZD, frizzled receptor; ITG, 
integrin-type receptors.
